VERAXA Biotech (NASDAQ: VRXA) has entered into a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC® pipeline of T-cell engagers and future antibody-drug conjugates, the company announced in a press release on July 13, 2026.
The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity. By integrating artificial intelligence into its research and development strategy, VERAXA believes it can enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity.
“We are excited to partner with Ardigen to leverage their AI capabilities to advance our BiTAC platform,” said a VERAXA spokesperson. The company expects the collaboration to strengthen the development of precision oncology therapies and improve long-term drug development success rates.
VERAXA Biotech is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
BiTAC® is a registered trademark of VERAXA Biotech GmbH. The full press release is available at https://ibn.fm/GLFg2.
Forward-looking statements in this article are subject to risks and uncertainties as described in the company’s filings with the SEC. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
